Home » Stocks » SPPI

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock Price: $3.07 USD -0.01 (-0.32%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 474.15M
Revenue (ttm) 109.33M
Net Income (ttm) -160.87M
Shares Out 155.71M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.07
Previous Close $3.08
Change ($) -0.01
Change (%) -0.32%
Day's Open 3.08
Day's Range 3.00 - 3.15
Day's Volume 1,926,870
52-Week Range 2.68 - 5.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

1 month ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

1 month ago - Business Wire

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

Other stocks mentioned: CTRM, CVM, MMEDF, MRO, YCBD
1 month ago - InvestorPlace

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #earnings--Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

1 month ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

1 month ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

1 month ago - Business Wire

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

1 month ago - Zacks Investment Research

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

Other stocks mentioned: ATNX, BLU, CPRX, NBEV, OPK, UEC
1 month ago - InvestorPlace

Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up.

5 months ago - Seeking Alpha

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

The company announced the pricing of a public offering of common stock.

9 months ago - The Motley Fool

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday.

9 months ago - 24/7 Wall Street

Spectrum scores a key win in the clinic with its experimental lung cancer drug.

9 months ago - The Motley Fool

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

Other stocks mentioned: XNCR
9 months ago - The Motley Fool

Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

11 months ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Shares jumped even though the company reported disappointing earnings. What can explain the boost?

1 year ago - The Motley Fool

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joseph Turgeon on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals (SPPI) closed the most recent trading day at $3.24, moving -1.52% from the previous trading session.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside

1 year ago - Seeking Alpha

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday.

1 year ago - Benzinga

Spectrum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares were halved on Thursday after the firm provided an update on its midstage cancer study.

1 year ago - 24/7 Wall Street

Spectrum Pharmaceuticals Inc. shares fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal.

1 year ago - Market Watch

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Spectrum Pharmaceuticals.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

1 year ago - Seeking Alpha

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 28.13% and -349.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.

Other stocks mentioned: ALXN, NVLN, NVS, ONCE
1 year ago - Benzinga

In the late 2000s, Spectrum captured the heightened demand of leucovorin shortage with Fusilev. This benefits patients while conferring shareholders one of the most prosperous periods in the company's h...

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

About SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with... [Read more...]

Industry
Biotechnology
IPO Date
Sep 26, 1996
Stock Exchange
NASDAQ
Ticker Symbol
SPPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SPPI stock is "Buy." The 12-month stock price forecast is 10.20, which is an increase of 232.25% from the latest price.

Price Target
$10.20
(232.25% upside)
Analyst Consensus: Buy